Study | Gene | Drug | Results | Quality (0–31) | Sample size |
---|---|---|---|---|---|
Benedetti et al.132 | COMT | Paroxetine | Rs4680 Met/Met ↑ response, Met/Val ↑↓ response, Val/Val ↓ response | 17 | 55 |
Leuchter et al.133 | COMT | Placebo | Rs4680 Met/Met ↓ placebo response | 15 | 132 |
Tsai et al.130 | COMT | Fluoxetine | Males rs4680 Met carriers ↑ response | 16 | 334 |
Perlis et al.134 | COMT | Duloxetine | rs165599 GG, rs165774 GG, rs174696 CC ↑ response | 13 | 102 |
Baune et al.131 | COMT | Various | Rs4680 Met/Met ↑ response | 18 | 256 |
Yoshida et al.129 | COMT | Milnacipram | Rs4680 Met/Met ↑ faster therapeutic effect | 18 | 81 |
Hu et al.135 | COMT | Bupropion | rs6277 TC genotype ↑ weight gain No association with body mass index or weight change | 16 | 283 |
Arias et al.122 | COMT | Various | Small effect on citalopram treatment result | 18 | 346 |
Szegedi et al.128 | COMT | Mirtazapine, paroxetine | Rs4680 ↑ mirtazapine response | 13 | 102 |
↑= positive association; ↓ = negative association.